---

Milk Products and Substitutes When a Lactating Mother Cannot Produce Enough Milk

Why a Mother May Fail to Produce Milk

• Insufficient or ineffective suckling (poor latch)
• Increased nutritional need (twins, rapid growth)
• Excessive fluid losses

• Failure to let down (stress, pain, anxiety)
• Primary glandular insufficiency
• Previous breast surgery or pathology
• Delayed secretory activation
• Certain medications (antihistamines, dopamine agonists, estrogen-containing contraceptives)
• Dysphoric milk-ejection reflex (D-MER) - a recently described condition where a sharp drop in dopamine at milk ejection causes maternal dysphoria and early weaning
• Maternal illness (chemotherapy, infections)
• Hormonal conditions (hypothyroidism, polycystic ovary syndrome)

---

The Hierarchy of Substitutes

1. Pasteurized Donor Human Milk (PDHM) - First Choice When Available

• Donors are screened for HIV, HTLV, Hepatitis B, Hepatitis C, syphilis, and lifestyle factors (alcohol, medications)
• Milk from multiple donors is pooled to ensure consistent caloric, protein, and immunological content
• "Holder pasteurization" (62.5°C for 30 minutes) is the standard method - it eliminates viruses and bacteria while preserving most immune-active components (lactoferrin, IgA, oligosaccharides)
• Every batch is tested before and after pasteurization for bacterial growth
• Banks operate under FDA regulation and HMBANA (Human Milk Banking Association of North America) guidelines

---

2. Infant Formula - Standard Alternative for Healthy Term Infants

---

Types of Infant Formula

A. Cow's Milk-Based Formula (Most Common)

---

B. Soy-Based Formula

---

C. Partially Hydrolyzed Formula ("Comfort" or "Gentle" Formula)

---

D. Extensively Hydrolyzed Formula (eHF)

---

E. Amino Acid-Based Formula (Elemental Formula)

---

F. Goat's Milk-Based Formula

---

G. Lactose-Free Cow's Milk Formula

---

H. Preterm/Premature Infant Formula

---

How Infant Formula Works

• Protein: Whey and casein in varying ratios; approximately 1.4-1.6 g/100 mL (lower than cow's milk)
• Fat: Vegetable oil blends providing essential fatty acids; DHA and ARA are commonly added to support brain and eye development
• Carbohydrate: Primarily lactose (mirrors breast milk); some use corn syrup solids or sucrose if lactose-free
• Micronutrients: Iron, calcium, phosphorus, zinc, vitamins A/C/D/E/K, and B-complex vitamins
• Added bioactives (modern formulas): Prebiotics (GOS, FOS), probiotics (Lactobacillus reuteri), nucleotides, and human milk oligosaccharide analogues - these aim to support immune function and gut microbiota development

---

Galactogogues - Medications to Boost Milk Supply First

• Domperidone (most commonly used; increases prolactin levels; not FDA-approved in the US but used internationally)
• Metoclopramide (used short-term; central dopamine antagonist; increases prolactin)
• Herbal galactogogues: Fenugreek, blessed thistle, fennel (evidence is limited; used empirically)
• Published reviews of galactogogues are available (Creasy & Resnik's, p. 248), though the evidence for many agents is modest

---

Safety Summary

---

Key References

1. Creasy & Resnik's Maternal-Fetal Medicine (9th ed.) - "Failing Milk Supply" and "Breastfeeding After Premature or Multiple Births" sections, pp. 248-249
2. Raiten DJ et al. (2016). Review of Infant Feeding: Key Features of Breast Milk and Infant Formula. Nutrients, PMC4882692
3. Haiden N, Savino F, Hill S et al. (2024). "Infant formulas for the treatment of functional gastrointestinal disorders: ESPGHAN Nutrition Committee position paper." J Pediatr Gastroenterol Nutr. [PMID 38766683]
4. Segura-Pérez S et al. (2022). "Risk factors for self-reported insufficient milk during the first 6 months of life: A systematic review." Matern Child Nutr. [PMID 35343065]
5. Schreiner C et al. (2023). "Microbiological Screening of Donor Human Milk." Breastfeed Med. [PMID 37971784]
6. Clifford V et al. (2025). "A Framework for Evaluation of New Processing Technologies in Human Milk Banking." Compr Rev Food Sci Food Saf. [PMID 41063490]
7. WHO International Code of Marketing of Breast-milk Substitutes (2024 update) - WHO IRIS document
8. University of Utah Health. Infant Formula Ingredients and Components. TRIP database, 2024.

---

Practical Summary

1. First: Work with a certified lactation consultant - most cases are remediable
2. Consider galactogogues if supply is borderline (domperidone, metoclopramide)
3. Prefer pasteurized donor human milk if available, especially for premature or low-birth-weight infants
4. Use cow's milk-based formula for healthy term infants when donor milk is unavailable
5. Choose specialized formula (hydrolyzed, soy, amino acid, or goat's milk) based on the infant's specific tolerance, medical condition, or family preferences
6. Never use unmodified cow's or goat's milk, home-made formula, or plant-based "milks" (oat, almond, rice) as primary nutrition for infants under 12 months

---

Research Papers: Donor Human Milk vs. Formula in Preterm Infants

---

Anchor: The Cochrane Review (Highest Evidence)

[Systematic Review + Meta-Analysis . Tier 1 . 2024]

---

Outcome 1 - Necrotizing Enterocolitis (NEC)

[Meta-Analysis . Tier 2 . 2020]

• Exclusive human milk vs. any formula: RR = 0.49 (95% CI 0.34-0.71), p <.05
• Dose-response relationship confirmed: the higher the proportion of human milk in the diet, the lower the NEC incidence
• Both mother's own milk and donor milk were protective; the effect was strongest with exclusive human milk diets

[Systematic Review + Meta-Analysis . Tier 1 . 2019]

• Focused specifically on surgical NEC (the most severe cases)
• 4 RCTs included
• DHM did not show a statistically significant protective effect against surgical NEC specifically: RR 0.45 (95% CI 0.19-1.09)
• Important nuance: The trend favors DHM but the confidence interval crosses 1.0, so no definitive conclusion for surgical NEC alone
• The authors note that stronger evidence is needed before recommending DHM solely as a strategy to prevent surgical NEC, and that mother's own milk remains the best option

---

Outcome 2 - RCT Evidence on NEC and Clinical Outcomes

[RCT . Tier 3 . 2013] - Landmark Trial

• Population: Extremely preterm infants whose mothers did not provide milk; randomized to exclusive bovine-based preterm formula (BOV) vs. exclusive donor human milk + human milk fortifier (HUM)
• NEC incidence: BOV 21% vs. HUM 3% (p = .08 overall)
• Surgical NEC: BOV 4 cases vs. HUM 0 cases (p = .04, significant)
• Parenteral nutrition duration: Significantly longer in BOV group (36 vs. 27 days, p = .04)
• Conclusion: Exclusive human milk diet significantly reduced surgical NEC and time on parenteral nutrition in extremely preterm infants

[RCT . Tier 3 . 2010]

• n = 207 extremely premature infants on three diet arms; compared exclusively human milk diet vs. a mixed diet containing bovine milk-based fortifier or preterm formula
• NEC rates: Significantly lower in the exclusively human milk groups (p = .02)
• Surgical NEC: Also significantly lower (p = .007)
• Growth rates and sepsis rates were similar between groups
• Conclusion: Even when mother's milk is supplemented with bovine products (fortifier or formula), NEC risk rises compared to an all-human-milk diet

[RCT . Tier 3 . 2005]

• n = 243 infants <30 weeks; randomized to DHM or preterm formula (PF) when mother's own milk supply was insufficient
• No significant difference between DHM and PF for LOS, NEC, other infections, hospital stay, or mortality
• However, mother's own milk (MOM) clearly outperformed both groups: fewer sepsis/NEC episodes, shorter hospital stay, fewer Gram-negative bacteremias
• 21% of DHM infants were switched to formula due to poor weight gain - an important finding
• Conclusion: DHM offered little short-term advantage over preterm formula when used as a supplement; the real benefit is mother's own milk. Note: this trial predates human milk-based fortifiers, which likely explains the poorer growth in the DHM arm

---

Outcome 3 - Neurodevelopmental Outcomes

[Systematic Review . Tier 1 . 2017]

• Volume of breast milk received is a key factor - higher volumes correlate with better neurodevelopmental outcomes
• Human milk feeding effects on cognition persist into adolescence
• Associated with increased white matter development and increased cortical thickness on structural brain imaging
• The bioactive components thought to drive better cognitive outcomes are long-chain polyunsaturated fatty acids (LCPUFAs) and human milk oligosaccharides (HMOs)
• Effects are sustained through childhood, not just the neonatal period

---

Outcome 4 - Growth

[Review . 2021]

• Infants fed donor milk may have slower weight gain than those fed exclusively maternal milk or formula - because DHM is more variable in composition and often lower in protein and calories after pasteurization
• Fortified maternal milk achieves weight gain comparable to preterm formula
• The solution is routine fortification of donor milk and point-of-care human milk analysis to individualize nutrient delivery
• Future directions include novel fortification approaches and better characterization of bioactive factor variation

---

Outcome 5 - Cost-Effectiveness

[RCT + Prospective Cost Analysis . Tier 3 . 2018]

• n = 363 VLBW infants; prospective cost analysis nested within an RCT
• NEC incidence: DHM 3.9% vs. formula 11.0% (p = .01) - significant reduction
• Total costs to 18 months: No significant difference (DHM ~CAD$217,624 vs. PTF ~CAD$217,245)
• Post-discharge costs: Lower in the DHM group (p = .04), driven mainly by reduced caregiver lost wages
• DHM cost an additional $5,328 per case of NEC averted
• Conclusion: DHM is not cost-saving overall but reduces NEC substantially and does not add to societal costs at 18 months, supporting its use

[Systematic Review . Tier 1 . 2017]

• Medical NEC adds ~18 days of hospital stay; surgical NEC adds ~50 days
• DHM likely provides short-term cost savings by reducing NEC incidence
• Full long-term economic evaluation including neurodevelopmental outcomes not yet available in the literature

---

Outcome 6 - Nutritional Interventions Overview

[Systematic Review of Meta-Analyses + RCTs . Tier 1 . 2020]

• Comprehensive review of all nutritional strategies in very preterm infants
• Pasteurized donor human milk vs. formula: reduced NEC but NOT infections or mortality (consistent with the Cochrane review)
• No difference between human milk-based vs. bovine milk-based fortifiers on outcomes
• Additional benefit found from: multi-strain probiotics (reduced NEC + mortality), enteral L-arginine (reduced NEC), bovine lactoferrin (reduced fungal sepsis), prebiotic oligosaccharides (reduced infections)

---

Current Clinical Guideline

[AAP Clinical Report . 2026]

• Mother's own milk (MOM), appropriately fortified, is optimal for VLBW infants
• Pasteurized donor human milk (PDHM) is recommended when MOM is unavailable, insufficient, or contraindicated
• PDHM should optimally be continued until NEC risk is low - approximately 34-36 weeks' postmenstrual age
• Preterm infant formula is recommended when MOM is unavailable AND PDHM is either unavailable or declined
• Promotion requires double electric pumps, skin-to-skin care, lactation support, and addressing social inequities in access

---

Summary of Evidence by Outcome

---

Bottom Line for Clinical Practice

1. DHM vs. formula for NEC prevention: Strong evidence - donor milk cuts NEC risk roughly in half. This is the primary clinical justification for its use.
2. DHM vs. formula for infection and mortality: No significant benefit of DHM over formula for these outcomes.
3. Growth trade-off: Unfortified donor milk produces slower weight gain than formula. Proper fortification closes this gap.
4. Neurodevelopment: Human milk diet (mother's own or donor) is associated with better long-term cognitive outcomes, but isolating donor milk specifically from mother's own milk is methodologically challenging.
5. The hierarchy remains: Mother's own milk > Pasteurized donor milk > Preterm formula - for VLBW infants in the NICU.